Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 07, 2026 09:00 ET | Source: SimpliFed

SimpliFed Raises Over $10 Million in an Oversubscribed Series A to Expand SimpliFed’s Maternal Health Ecosystem

ITHACA, NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- SimpliFed, the maternal healthcare leader in providing virtual breastfeeding and baby feeding support for new parents, announced today that it...
April 07, 2026 09:00 ET | Source: CloudBolt

CloudBolt Research Exposes the “Trust Gap” Blocking Kubernetes Optimization

CloudBolt Software, announced the release of its latest CloudBolt Industry Insights (CII) report, “The Kubernetes Automation Trust Gap No One Talks About."
April 07, 2026 07:45 ET | Source: Wrap Technologies, Inc.

Galveston Police Department Adopts Non-Lethal Response Solutions with Purchase of BolaWrap® Devices and WrapTactics™ Subscription, Supported by In-Person Training as Part of Broader NLR Strategy

Galveston Police Adopts Non-Lethal Response Solutions with Purchase of BolaWrap® Devices and WrapTactics™ Subscription as Part of Broader NLR Strategy
April 07, 2026 07:09 ET | Source: Pluristyx, Inc.

Pluristyx Extends Patent Portfolio in Universal Cell Therapy with New U.S. Patent for iACT Stealth™ Technology

Pluristyx announces a new U.S. patent for iACT Stealth™ technology, enabling "cloaking" of cells to treat autoimmune diseases without immune suppression.
April 07, 2026 07:00 ET | Source: MediWound Ltd.

MediWound to Present New EscharEx® Data at Leading Wound Care Conferences

MediWound to Present New EscharEx® Data at Leading Wound Care Conferences Data highlights mechanism of action, outcomes in VLUs and DFUs, and comparative advantages over SANTYL® Findings support...
April 06, 2026 19:02 ET | Source: Organogenesis Holdings Inc.

Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AM

Statistically significant (p<0.0477) DFU wound closure at 12 weeksRCT compared PuraPly®AM plus standard of care to standard of care aloneResults strengthen existing clinical evidence supporting...
April 06, 2026 17:30 ET | Source: Organogenesis Holdings Inc.

Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain

Clinical Development Program Appropriate for Rolling BLA Submission Expected by the End of 2025 CANTON, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a...
April 06, 2026 16:05 ET | Source: Outset Medical, Inc.

Outset Medical Names Derick Elliott as Executive Vice President of Commercial

SAN JOSE, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in...
April 06, 2026 07:30 ET | Source: Organogenesis Holdings Inc.

Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026

CANTON, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the...
April 03, 2026 16:01 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on April...